Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.55 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.54 |
| ▸ | FNTA | P49354 | 1/20 | 0.49 |
| ▸ | FNTB | P49356 | 1/20 | 0.49 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.49 |
| ▸ | PLAU | P00749 | 2/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.46 |
| ▸ | PLAT | P00750 | 1/20 | 0.46 |
| ▸ | IL2 | P60568 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6480284 | 0.88 | ERN1 (0.56) | ERN1LOXL2CA12CA9CA1 | |
| SCHEMBL1495847 | 0.84 | LOXL2 (0.54) | LOXL2CA12CA9CA1CA2 | |
| Hydrochloric Acid SCHEMBL12499887 | 0.83 | LOXL2 (0.53) | LOXL2CA12CA9CA1CA2 | |
| SCHEMBL2569067 | 0.81 | LOXL2 (0.71) | ERN1LOXL2CA12CA9CA1 | |
| SCHEMBL2940473 | 0.79 | BDKRB1 (0.72) | BDKRB1 | |
| SCHEMBL67941 | 0.79 | CA12 (0.68) | ERN1LOXL2CA12CA9CA1 | |
| SCHEMBL27405638 | 0.79 | LOXL2 (0.82) | ERN1LOXL2CA12CA9CA1 | |
| SCHEMBL6489508 | 0.78 | LMNA (0.54) | ERN1PDK2NPC1RAB9ABDKRB1 | |
| SCHEMBL7816934 | 0.78 | CA12 (0.64) | ERN1CA12CA9CA1CA2 | |
| Hydrochloric Acid SCHEMBL5923244 | 0.78 | BDKRB1 (0.71) | BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6953810-B2 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC (US) | 2005-10-11 | — | — | US | disclosed |
| US-20040048903-A1 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. | 2004-03-11 | — | — | US | disclosed |
| US-6649633-B2 | For treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease | PFIZER INC | 2003-11-18 | — | — | US | disclosed |
| EP-1355884-A1 | NICOTINAMIDE BIARYL DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | Pfizer Products Inc. (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20020193612-A1 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. | 2002-12-19 | — | — | US | disclosed |
| WO-2002060875-A1 | NICOTINAMIDE BIARYL DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193612-A1 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | CBR1, CBR3, NOX1 | ERN1 879/4885LOXL2 1496/4885CA12 4115/4885 |
| US-20040048903-A1 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | CBR1, CBR3, NOX1 | ERN1 877/4885LOXL2 1515/4885CA12 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.